Kolkata City Doctors Seek Cap on Insulin Prices Amid Rising Healthcare Costs

Kolkata’s leading physicians have petitioned the municipal authorities to impose a maximum price on insulin, a drug that has seen a steep rise in cost over the past decade. The appeal reflects growing concern over the affordability of life‑saving medication for the city’s diabetic population, many of whom rely on subsidized healthcare.

The demand for a price cap highlights the broader tension between pharmaceutical innovation and patient access. While manufacturers argue that high prices fund research and development, the medical community insists that the current rates render insulin unaffordable for a significant segment of the population.

Should the city enact the proposed cap, it would set a precedent for other municipalities, potentially prompting national regulators to revisit pricing frameworks. The move could also influence the competitive dynamics of the insulin market, encouraging domestic manufacturers to increase production and reduce dependence on imported brands.